ASRT vs. NLTX, VRCA, STTK, AMRN, VTYX, PGEN, NBTX, XERS, SKYE, and QTTB
Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Neoleukin Therapeutics (NLTX), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), Amarin (AMRN), Ventyx Biosciences (VTYX), Precigen (PGEN), Nanobiotix (NBTX), Xeris Biopharma (XERS), Skye Bioscience (SKYE), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical preparations" industry.
Assertio (NASDAQ:ASRT) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Assertio received 55 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 58.99% of users gave Assertio an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -234.40%. Assertio's return on equity of 10.80% beat Neoleukin Therapeutics' return on equity.
Assertio has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
49.0% of Assertio shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 3.2% of Assertio shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Assertio had 9 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 9 mentions for Assertio and 0 mentions for Neoleukin Therapeutics. Assertio's average media sentiment score of 0.62 beat Neoleukin Therapeutics' score of 0.00 indicating that Assertio is being referred to more favorably in the media.
Neoleukin Therapeutics has lower revenue, but higher earnings than Assertio. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Assertio currently has a consensus price target of $4.58, indicating a potential upside of 360.73%. Given Assertio's higher possible upside, equities analysts plainly believe Assertio is more favorable than Neoleukin Therapeutics.
Summary
Assertio beats Neoleukin Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Assertio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assertio Competitors List
Related Companies and Tools
